Figure 4: Serum level of glutamate for the 5 experimental groups: control, tumour, tum+FLX, tum+SSZ, tum+5-ASA/SP.

Data are presented as mean ± SEM. No significant differences were observed between treatment groups. Trends were consistent with the expected increase of serum glutamate in tumour-bearing mice, and the expected inhibition of cancer cell glutamate release by SSZ. Results were analyzed using one-way ANOVA. The Holm-Šidák correction was used to correct for multiple comparisons.